|
|
| (6 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Fatty liver]] |
| | |
| {{Editor Help}}
| |
| | |
| ==Overview==
| |
| {{Infobox_Disease |
| |
| Name = {{PAGENAME}} |
| |
| Image = Alcoholic hepatitis 1.jpg |
| |
| Caption = |
| |
| DiseasesDB = |
| |
| ICD10 = |
| |
| ICD9 = |
| |
| ICDO = |
| |
| OMIM = |
| |
| MedlinePlus = |
| |
| eMedicineSubj = |
| |
| eMedicineTopic = |
| |
| MeshID = |
| |
| }}
| |
| {{Search infobox}}
| |
| '''Steatohepatitis''' is a type of [[liver disease]], characterized by [[inflammation]] of the [[liver]] with concurrent [[fat]] accumulation in liver ("steato", meaning fat, "[[hepatitis]]", meaning inflammation of the liver). Classically seen in alcoholics, steatohepatitis also is frequently found in people with [[diabetes]] and [[obesity]]. When not associated with excessive [[alcohol]] intake, it's referred to as "[[non-alcoholic steatohepatitis]]", or NASH. Steatohepatitis of either [[etiology]] may progress to [[cirrhosis]], and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies).
| |
| | |
| Steatohepatitis is characterized microscopically by hepatic fat accumulation ([[steatosis]]), mixed lobular inflammation, ballooning degeneration of [[hepatocyte]]s (sometimes with identifiable [[Mallory bodies]]), [[glycogen]]ated hepatocyte nuclei, and pericellular [[fibrosis]]. The "chicken wire" pattern of the pericellular fibrosis, which affects portal areas only secondarily in later stages, is very characteristic and is identified on trichrome stains.
| |
| | |
| | |
| | |
| ==Treatment==
| |
| | |
| Recent studies suggest that [[diet (nutrition)|diet]], [[exercise]], and especially [[anti-diabetic drug|antiglycemic drug]]s may alter the course of the disease. A [[randomized controlled trial]] found that "[[pioglitazone]] led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis".<ref name="pmid17135584">{{cite journal |author=Belfort R, Harrison SA, Brown K, ''et al'' |title=A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis |journal=N. Engl. J. Med. |volume=355 |issue=22 |pages=2297–307 |year=2006 |pmid=17135584 |doi=10.1056/NEJMoa060326}}</ref>
| |
| | |
| ==Prognosis==
| |
| A retrospective [[cohort study]] concluded that "liver failure is the main cause of morbidity
| |
| and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe
| |
| than HCV-cirrhosis."<ref name="pmid12883486">{{cite journal |author=Hui JM, Kench JG, Chitturi S, ''et al'' |title=Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C |journal=Hepatology |volume=38 |issue=2 |pages=420–7 |year=2003 |pmid=12883486 |doi=10.1053/jhep.2003.50320}}</ref>
| |
| | |
| ==References==
| |
| <references/>
| |
| | |
| ==See also==
| |
| *[[fatty liver|steatosis hepatis]]
| |
| *[http://hepatitis-central.com/hcv/info/2003/aug/hepcinfo420.pdf Hepatitis C]Long-Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
| |
| | |
| {{SIB}}
| |
| {{Symptoms and signs}}
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
| | |
| [[Category:Hepatitis]]
| |
| [[Category:Gastroenterology]]
| |